Virtus Fund Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Virtus Fund Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-878	Closed	-$23.5K	–	123
2024 Q2	$23.5K	Buy	878 +164	+23%	+$4.75K	0.09%	103
2024 Q1	$24.4K	Hold	714	–	–	0.09%	99
2023 Q4	$20.7K	Hold	714	–	–	0.13%	97
2023 Q3	$19.7K	Hold	714	–	–	0.14%	95
2023 Q2	$21.5K	Hold	714	–	–	0.15%	94
2023 Q1	$25.9K	Buy	+714	New	+$27.5K	0.18%	87
2017 Q4	$333K	Sell	8,355 -709	-8%	-$28K	﹤0.01%	434
2017 Q3	$363K	Sell	9,064 -564	-6%	-$24.4K	﹤0.01%	325
2017 Q2	$415K	Sell	9,628 -287	-3%	-$10.2K	﹤0.01%	330
2017 Q1	$310K	Buy	+9,915	New	+$266K	﹤0.01%	378
2014 Q3	–	Sell	-2,498	Closed	-$27K	–	1847
2014 Q2	$27K	Buy	+2,498	New	+$22.3K	﹤0.01%	2268

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus Fund Advisers's SUPN Position: Q3 2024 in Review

Virtus Fund Advisers sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 878 shares — an estimated $23.5K sold.

Virtus Fund Advisers first reported a position in SUPN in Q2 2014 and held it in 11 quarters. The position peaked at $415K in Q2 2017. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

Virtus Fund Advisers reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Virtus Fund Advisers sold 878 Supernus Pharmaceuticals shares in Q3 2024, an estimated $23.5K.
Virtus Fund Advisers first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 11 quarters.
Virtus Fund Advisers's Supernus Pharmaceuticals position peaked at $415K in Q2 2017.
273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on Virtus Fund Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.